Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

23,712articles mentioning diseases

125,551disease mentions

18,081distinct diseases extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted diseases

Showing 10,981–11,040 of 18,081, ordered by supporting articles. Choose a disease to see its evidence.

Phelan McDermid syndrome1 Phelan-McDermid syndrome1 Philadelphia-negative chronic myeloproliferative neoplasms1 Phosphaturic mesenchymal tumours1 Phosphaturic mesenchymal tumours (PMTs)1 Physical inactivity1 PiZZ AATD1 Placenta accreta spectrum (PAS)1 Placental site trophoblastic tumour (PSTT)1 Plasmodium vivax1 Plasmodium vivax malaria1 Platypnoea Orthodeoxia syndrome1 Pleomorphic adenoma of the lacrimal gland1 Plummer–Vinson syndrome1 Pneumatosis cystoides intestinalis1 Pneumocephalus1 Pneumocystis jirovecii1 Pneumocystis jirovecii pneumonia (PJP)1 Pneumonia31 Pocket haematoma1 Polymyositis-Scleroderma1 Polyp cancers1 Polyradiculoneuropathy1 Popeye deformity1 Popliteal Plexus Block (PPB)1 Portal cavernoma (PC)1 Portal hypertension (PHTN)1 Portal vein thrombosis (PVT)1 Porto-sinusoidal vascular disease (PSVD)1 Post- Covid1 Post-COVID-19 syndrome1 Post-Stroke Cognitive Impairment1 Post-induction hypotension (PIH)1 Post-ligation cardiac syndrome (PLCS)1 Post-mastectomy Pain Syndrome (PMPS)1 Post-operative pain1 Post-procedural myocardial infarction1 Post-stroke cognitive impairment (PSCI)1 Post-subarachnoid haemorrhage-induced (SAH) vasospasm1 Post-surgical pain syndrome-thoracolumbar1 Post-traumatic chronic pain (PTCP)1 Post-tuberculosis lung disease (PTLD)1 Posterior capsule opacification (PCO)1 Posterior circulation (PC) aneurysms1 Posterior communicating artery (PCoM) aneurysms1 Posterior condylar canal dural arteriovenous fistula1 Posterior cutaneous nerve entrapment syndrome1 Postextubation swallowing disorders1 Postictal agitation1 Postmenopausal bleeding1 Postoperative atrial fibrillation (POAF)1 Postoperative microbial keratitis (MK)1 Postoperative pancreatic fistula1 Postoperative sore throat (POST)1 Postoperative urinary retention (POUR)1 Postpartum haemorrhage101 Postpartum reversible cerebral vasoconstriction syndrome (RCVS)1 Postpneumonectomy syndrome1 Postprandial distress syndrome1 Poststroke cognitive impairment (PSCI)1

View all 18,081 diseases on one page

Articles mentioning diseases

23,712 articles · page 401 of 1976

4CPS-044 Comparison of the effectiveness of atogepant combined with botulinum toxin versus atogepant monotherapy in the prevention of chronic migraine

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

98.9%

chronic migraine CM atogepant BTX-ATO ATOm

…elevance Results suggest that the effectiveness of atogepant in chronic migraine, in terms of reducing monthly migraine days, is comparable betw…

4CPS-077 Effectiveness of faricimab treatment: real-world study in a tertiary hospital

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

97.5%

diabetic macular oedema neovascular age-related macular degeneration nAMD DME faricimab ranibizumab aflibercept brolucizumab

…ment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). Unlike previous anti-VEGF agents, faricimab targets both…

4CPS-096 The impact of pharmaceutical interventions on the management of hospitalised patients with cirrhosis: what role does the clinical pharmacist play?

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

95.4%

hepatic impairment cirrhosis hepatic insufficiency beta-blockers secondary care hospital psycholeptics hypolipidemic agents Society of Hospital Pharmacists of Australia

…y, is limited. The adaptation of drug dosages in the context of hepatic impairment is a complex issue that lacks comprehensive discussion in curre…

4CPS-124 Off-label use of dalbavancin in real-world clinical practice: a retrospective observational study

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

94.8%

ABSSSI osteomyelitis spondylodiscitis acute bacterial skin and skin structure infections prosthetic joint infection complex infections dalbavancin Ambulatory consolidation therapy Hospital Pharmacy Department

…odality. Off-label use was defined as any indication other than ABSSSI. A stepwise backward selection linear regression model was used…

4CPS-140 Off-label use of sodium zirconium cyclosilicate in acute severe hyperkalaemia: evaluation of use conditions and effectiveness

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

96.7%

acute severe hyperkalaemia chronic hyperkalaemia acute hyperkalaemia renal failure calcium gluconate insulin intravenous glucose SZC tertiary hospital

…tiation.SZC appears to be an effective adjunctive treatment for acute severe hyperkalaemia in patients with renal failure who are already receiving standa…

4CPS-148 Effectiveness and safety of atogepant in the preventive treatment of migraine

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

93.0%

migraine episodic migraine atogepant

…ly approved oral calcitonin gene-related peptide antagonist for migraine prophylaxis in adults. Real-world data on its efficacy and safe…

4CPS-162 Real-world evidence with ofatumumab in multiple sclerosis

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

97.4%

multiple sclerosis MS SPMS RRMS ofatumumab ocrelizumab teriflunomide natalizumab

… all patients with relapsing-remitting or secondary progressive multiple sclerosis (RRMS; SPMS), who initiated Ofatumumab between January 2023 and…

4CPS-168 Effectiveness, quality of life and safety of atogepant for migraine prophylaxis

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

94.4%

migraine CM Atogepant Neurology Department Ethics Committee

…ts calcitonin gene-related peptide (CGRP) receptors involved in migraine development.Aim and Objectives To evaluate atogepant effectiven…

4CPS-193 Descriptive real-world outcomes with aflibercept 8 mg/0.07 ml in wet age-related macular degeneration and diabetic macular oedema

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

95.9%

diabetic macular oedema wet age-related macular degeneration DME AMD Aflibercept

…the treatment of wet age-related macular degeneration (AMD) and diabetic macular oedema (DME) in adults.Aim and Objectives To evaluate the use of aflib…

4CPS-238 Pharmaceutical care programme for patients undergoing allogeneic haematopoietic stem cell transplantation (PHARALLO): impact on clinical outcomes

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

94.0%

aGVHD aGVHD-cumulative-incidence acute renal failure acute graft-versus-host disease aGVHD-related aGVHD-free European Society for Blood and Marrow Transplantation PHARALLO EBMT

…luded (37 intervention; 30 control).The cumulative incidence of aGVHD by day +100 was reduced by 13.4% in the intervention group (p=0…

4CPS-259 Impact of switching to biosimilar etanercept in rheumatoid arthritis patients followed in pharmaceutical consultations at a tertiary hospital

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

96.7%

Rheumatoid arthritis RA Erelzi Benepali Enbrel

…Background and Importance Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic joint disease. Although…

4CPS-263 Evaluation of the efficacy and safety of anti-CGRP monoclonal antibodies (MABS) for the treatment of migraine at a central hospital

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

99.3%

migraine Headache CGRP galcanezumab erenumab fremanezumab

…, anti-CGRP mAbs were associated with significant reductions in migraine frequency after 6 months. Galcanezumab showed the greatest mean…